Parallax Volatility Advisers, L.P. Fate Therapeutics Inc Transaction History

Parallax Volatility Advisers, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $7,579 - $20,089	199 New	199 $18,000
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $236,982 - $413,106	-11,726 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $19,388 - $35,769	1,122 Added 10.58%	11,726 $260,000
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $141,987 - $219,820	10,604 New	10,604 $208,000
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $78,050 - $102,200	-5,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$13.15 - $18.71 $65,750 - $93,550	5,000 New	5,000 $88,000
Q1 2018 May 15, 2018	SELL	$6.3 - $13.77 $36,514 - $79,810	-5,796 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $22,836 - $38,485	5,796	5,796 $35,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.